Population Pharmacokinetic and Pharmacodynamic Modeling of LY2510924 in Patients With Advanced Cancer

por Bihorel, S, Raddad, E, Fiedler‐Kelly, J, Stille, JR, Hing, J, Ludwig, E
Publicado 2017

Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance

por Hing, J.X., Mok, C.W., Tan, P.T., Sudhakar, S.S., Seah, C.M., Lee, W.P., Tan, S.M.
Publicado 2020